

# Paola Cipriani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3353462/publications.pdf>

Version: 2024-02-01

142  
papers

5,609  
citations

61857

43  
h-index

98622

67  
g-index

143  
all docs

143  
docs citations

143  
times ranked

6409  
citing authors

#	ARTICLE	IF	CITATIONS
1	Correspondence on "Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis". <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e119-e119.	0.5	1
2	Response to: "Correspondence on "Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence" radiological differences" by Ruscitti et al" by Chen et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e221-e221.	0.5	1
3	Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study. <i>Clinical Rheumatology</i> , 2022, 41, 641-647.	1.0	6
4	Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Uveitis. <i>Ophthalmology and Therapy</i> , 2022, 11, 899-911.	1.0	14
5	Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases. <i>Clinical Rheumatology</i> , 2022, 41, 2261-2267.	1.0	7
6	Unenhanced Cardiac Magnetic Resonance may improve detection and prognostication of an occult heart involvement in asymptomatic patients with systemic sclerosis. <i>Scientific Reports</i> , 2022, 12, 5125.	1.6	3
7	Development and Implementation of the AIDA International Registry for Patients With Still's Disease. <i>Frontiers in Medicine</i> , 2022, 9, 878797.	1.2	9
8	Novel biomarker for pulmonary vascular disease in systemic sclerosis patients. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	2
9	Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications. <i>Autoimmunity Reviews</i> , 2022, 21, 103114.	2.5	12
10	Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF- $\beta$ 2 and IL-6. <i>Pharmaceuticals</i> , 2022, 15, 622.	1.7	7
11	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. <i>Autoimmunity Reviews</i> , 2021, 20, 102738.	2.5	38
12	Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2021, 20, 102735.	2.5	135
13	Dissecting the clinical heterogeneity of adult-onset Still's disease: results from a multi-dimensional characterization and stratification. <i>Rheumatology</i> , 2021, 60, 4844-4849.	0.9	23
14	Evaluating the multivisceral involvement on adult-onset Still's disease to retrieve imaging-based differences in patients with and without macrophage activation syndrome: results from a single-centre observational study. <i>Clinical Rheumatology</i> , 2021, 40, 3971-3978.	1.0	5
15	Association Between Minor Salivary Gland Biopsy During Sjögren's Syndrome and Serologic Biomarkers: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 686457.	2.2	6
16	The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile. <i>Scientific Reports</i> , 2021, 11, 12455.	1.6	10
17	Pathogenic implications, incidence, and outcomes of COVID-19 in autoimmune inflammatory joint diseases and autoinflammatory disorders. <i>Advances in Rheumatology</i> , 2021, 61, 45.	0.8	7
18	Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 213.	1.6	25

#	ARTICLE	IF	CITATIONS
19	Long-term safety of rituximab in primary Sjögren's syndrome: the experience of a single centre. <i>Journal of Rheumatology</i> , 2021, , jrheum.210441.	1.0	1
20	Duration of clinical remission and low disease activity impacts on quality of life and its domains in psoriatic arthritis patients: results from an Italian multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
21	The Effect of Ketogenic Diet on Inflammatory Arthritis and Cardiovascular Health in Rheumatic Conditions: A Mini Review. <i>Frontiers in Medicine</i> , 2021, 8, 792846.	1.2	22
22	The clinical heterogeneity of adult onset Still's disease may underlie different pathogenic mechanisms. Implications for a personalised therapeutic management of these patients. <i>Seminars in Immunology</i> , 2021, 58, 101632.	2.7	10
23	Adipose stromal vascular fraction and regenerative therapy in SSC: response to the article by Magalon et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e53-e53.	0.5	3
24	Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis. <i>Journal of Dermatological Treatment</i> , 2020, 31, 692-697.	1.1	5
25	Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort. <i>Rheumatology International</i> , 2020, 40, 107-113.	1.5	20
26	Hepatitis E Virus and rheumatic diseases: what do rheumatologists need to know?. <i>BMC Rheumatology</i> , 2020, 4, 51.	0.6	10
27	Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations. <i>Scientific Reports</i> , 2020, 10, 12232.	1.6	38
28	Haematopoietic stem cell transplantation in systemic sclerosis: Challenges and perspectives. <i>Autoimmunity Reviews</i> , 2020, 19, 102662.	2.5	5
29	The wide spectrum of Kawasaki-like disease associated with SARS-CoV-2 infection. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1205-1215.	1.3	12
30	Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1515-1516.	0.5	36
31	Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm. <i>Frontiers in Immunology</i> , 2020, 11, 1130.	2.2	79
32	Parenchymal lung disease in adult onset Still's disease: an emergent marker of disease severity" characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients. <i>Arthritis Research and Therapy</i> , 2020, 22, 151.	1.6	38
33	Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension. <i>Arthritis Research and Therapy</i> , 2020, 22, 127.	1.6	18
34	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , 2020, 7, 42.	1.2	21
35	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the "multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort. <i>PLoS ONE</i> , 2020, 15, e0235326.	1.1	31
36	Glucocorticoids in rheumatoid arthritis: the silent companion in the therapeutic strategy. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 593-604.	1.3	13

#	ARTICLE	IF	CITATIONS
37	Advanced diagnostic imaging and intervention in tendon diseases. <i>Acta Biomedica</i> , 2020, 91, 98-106.	0.2	2
38	Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1247-1254.	0.4	22
39	Title is missing!. , 2020, 15, e0235326.		0
40	Title is missing!. , 2020, 15, e0235326.		0
41	Title is missing!. , 2020, 15, e0235326.		0
42	Title is missing!. , 2020, 15, e0235326.		0
43	Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCs (Gruppo Italiano di Ricerca in Reumatologia Clínica e Sperimentale) study. <i>Arthritis Research and Therapy</i> , 2019, 21, 204.	1.6	40
44	Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. <i>PLoS Medicine</i> , 2019, 16, e1002901.	3.9	94
45	Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands. <i>PLoS ONE</i> , 2019, 14, e0211142.	1.1	11
46	Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling. <i>Scientific Reports</i> , 2019, 9, 7144.	1.6	18
47	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019, 10, 296.	1.6	35
48	Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts. <i>Scientific Reports</i> , 2019, 9, 4589.	1.6	12
49	IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes. <i>Medicine (United States)</i> , 2019, 98, e14587.	0.4	36
50	Hepatitis E infection in a patient with rheumatoid arthritis treated with leflunomide. <i>Medicine (United States)</i> , 2019, 98, e14587.	0.4	6
51	Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study. <i>Medicine (United States)</i> , 2019, 98, e14587.	0.4	6
52	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. <i>Autoimmunity Reviews</i> , 2019, 18, 93-106.	2.5	101
53	Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review). <i>Molecular Medicine Reports</i> , 2019, 20, 1488-1498.	1.1	10
54	The kaleidoscope of neurological manifestations in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 192-198.	0.4	9

#	ARTICLE	IF	CITATIONS
55	The Vessels Contribute to Fibrosis in Systemic Sclerosis. <i>Israel Medical Association Journal</i> , 2019, 21, 471-474.	0.1	10
56	Vitamin D increases the production of IL-10 by regulatory T cells in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 76-81.	0.4	6
57	Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort. <i>Journal of Rheumatology</i> , 2018, 45, 864-872.	1.0	70
58	Interleukin-25 Axis Is Involved in the Pathogenesis of Human Primary and Experimental Murine Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 1265-1275.	2.9	18
59	The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. <i>Modern Rheumatology</i> , 2018, 28, 922-932.	0.9	21
60	Scleroderma fibroblasts suppress angiogenesis via TGF- $\beta$ 2/caveolin-1 dependent secretion of pigment epithelium-derived factor. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 431-440.	0.5	26
61	Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities. <i>Journal of Immunology Research</i> , 2018, 2018, 1-10.	0.9	20
62	Tailored approach to rheumatoid arthritis treatment with TNF inhibitors: where do we stand?. <i>Rheumatology</i> , 2018, 57, vii1-vii4.	0.9	1
63	Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy. <i>Arthritis Research and Therapy</i> , 2018, 20, 223.	1.6	29
64	Downregulation of miRNA17-92 cluster marks V $\beta$ 2 T cells from patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 236.	1.6	20
65	Laboratory Assessment of Patients with Suspected Rheumatic Musculoskeletal Diseases: Challenges and Pitfalls. <i>Current Rheumatology Reviews</i> , 2018, 15, 27-43.	0.4	6
66	Interstitial lung disease in systemic sclerosis: current and future treatment. <i>Rheumatology International</i> , 2017, 37, 853-863.	1.5	76
67	Computed Tomography and MR Imaging in Rheumatoid Arthritis. <i>Radiologic Clinics of North America</i> , 2017, 55, 997-1007.	0.9	74
68	Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic sclerosis patients of recent onset. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1247-1260.	0.9	15
69	PTP4A1 promotes TGF- $\beta$ 2 signaling and fibrosis in systemic sclerosis. <i>Nature Communications</i> , 2017, 8, 1060.	5.8	46
70	Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 1041-1047.	1.3	36
71	Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis. <i>Medicine (United States)</i> , 2017, 96, e7896.	0.4	42
72	Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients. <i>Clinical Rheumatology</i> , 2017, 36, 2839-2845.	1.0	53

#	ARTICLE	IF	CITATIONS
73	Biologic drugs in adult onset Stillé™s disease: a systematic review and meta-analysis of observational studies. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 1089-1097.	1.3	42
74	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, Sjögren's syndrome, etc.). <i>Journal of Autoimmunity</i> , 2017, 30, 1-10.	2.5	107
75	Phenotypical and Functional Characteristics of in Vitro-Expanded Adipose-Derived Mesenchymal Stromal Cells from Patients with Systemic Sclerosis. <i>Cell Transplantation</i> , 2017, 26, 841-854.	1.2	31
76	Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study. <i>Clinical Rheumatology</i> , 2017, 36, 251-260.	1.0	22
77	Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers. <i>Autoimmunity Reviews</i> , 2017, 16, 16-21.	2.5	65
78	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Stillé™s Disease: A Multicentre Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2017, 8, 369.	1.6	89
79	Increased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1 Year Prospective Single Centre Study. <i>PLoS ONE</i> , 2017, 12, e0170108.	1.1	41
80	Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. <i>PLoS ONE</i> , 2017, 12, e0181203.	1.1	42
81	Searching for a good model for systemic sclerosis: the molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis. <i>Archives of Medical Science</i> , 2016, 4, 828-843.	0.4	7
82	Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study. <i>Clinical and Experimental Immunology</i> , 2016, 184, 284-292.	1.1	32
83	Adult-onset Stillé™s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. <i>BMC Medicine</i> , 2016, 14, 194.	2.3	130
84	Endothelial progenitor cells: Are they displaying a function in autoimmune disorders?. <i>Mechanisms of Ageing and Development</i> , 2016, 159, 44-48.	2.2	13
85	Interleukin-9 Overexpression and Th9 Polarization Characterize the Inflamed Gut, the Synovial Tissue, and the Peripheral Blood of Patients With Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1922-1931.	2.9	80
86	Perivascular Cells in Diffuse Cutaneous Systemic Sclerosis Overexpress Activated ADAM12 and Are Involved in Myofibroblast Transdifferentiation and Development of Fibrosis. <i>Journal of Rheumatology</i> , 2016, 43, 1340-1349.	1.0	45
87	Mesenchymal Stem Cell Transplantation in Systemic Sclerosis: Comment on the Article by Maria et al. <i>Arthritis and Rheumatology</i> , 2016, 68, 2348-2348.	2.9	1
88	IL-1 $\beta$ at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 849-855.	1.3	46
89	Safety and efficacy of intra-articular anti-tumor necrosis factor $\beta$ agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare. <i>International Journal of Immunopathology and Pharmacology</i> , 2016, 29, 252-266.	1.0	32
90	Comment on "Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?". <i>Autoimmunity Reviews</i> , 2016, 15, 202.	2.5	0

#	ARTICLE	IF	CITATIONS
91	Persistence of focal lymphocytic sialadenitis in patients with primary Sjögren's syndrome treated with rituximab: a possible role for glandular BAFF. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 1123-1124.	0.4	4
92	Erratum to "œls minor salivary gland biopsy more than a diagnostic tool in primary Sjögren's syndrome? Association between clinical, histopathological, and molecular features: A retrospective study" [Semin Arthritis Rheum 44 (2014) 314-324]. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, e23.	1.6	0
93	Use of Rituximab in the Management of Sjögren's Syndrome. <i>Current Treatment Options in Rheumatology</i> , 2015, 1, 277-291.	0.6	3
94	Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. <i>Journal of Medical Case Reports</i> , 2015, 9, 123.	0.4	28
95	Macitentan inhibits the transforming growth factor- $\beta$ profibrotic action, blocking the signaling mediated by the ETR/T $\beta$ RI complex in systemic sclerosis dermal fibroblasts. <i>Arthritis Research and Therapy</i> , 2015, 17, 247.	1.6	22
96	Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjögren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18. <i>Clinical and Experimental Immunology</i> , 2015, 181, 219-229.	1.1	38
97	Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1 $\beta$ via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3 (NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. <i>Clinical and Experimental Immunology</i> , 2015, 182, 35-44.	1.1	100
98	T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and Perspectives. <i>Mediators of Inflammation</i> , 2015, 2015, 1-10.	1.4	59
99	The Role of IL-1 $\beta$ in the Bone Loss during Rheumatic Diseases. <i>Mediators of Inflammation</i> , 2015, 2015, 1-10.	1.4	146
100	Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. <i>Autoimmunity Reviews</i> , 2015, 14, 429-437.	2.5	46
101	Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. <i>Cytotherapy</i> , 2015, 17, 832-849.	0.3	19
102	Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?. <i>Autoimmunity Reviews</i> , 2015, 14, 575-578.	2.5	31
103	The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor- $\beta$ and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. <i>Journal of Rheumatology</i> , 2015, 42, 1808-1816.	1.0	82
104	A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sjögren's syndrome. <i>Lupus</i> , 2015, 24, 315-320.	0.8	63
105	Stem cell therapies for systemic sclerosis. <i>British Journal of Haematology</i> , 2015, 168, 328-337.	1.2	11
106	Myositis in primary Sjögren's syndrome: data from a multicentre cohort. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 457-64.	0.4	27
107	Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome. <i>Rheumatology</i> , 2014, 53, 1313-1320.	0.9	41
108	Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis. <i>Fibrogenesis and Tissue Repair</i> , 2014, 7, 13.	3.4	24

#	ARTICLE	IF	CITATIONS
109	Impaired Endothelium-Mesenchymal Stem Cells Cross-talk in Systemic Sclerosis: a Link Between Vascular and Fibrotic Features. <i>Arthritis Research and Therapy</i> , 2014, 16, 442.	1.6	49
110	CD4 <sup>+</sup> CD8 <sup>+</sup> T-cells in primary Sjögren's syndrome: Association with the extent of glandular involvement. <i>Journal of Autoimmunity</i> , 2014, 51, 38-43.	3.0	60
111	Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. <i>Clinical Rheumatology</i> , 2014, 33, 49-55.	1.0	84
112	Methotrexate in Rheumatoid Arthritis: Optimizing Therapy Among Different Formulations. <i>Current and Emerging Paradigms. Clinical Therapeutics</i> , 2014, 36, 427-435.	1.1	62
113	Unmasking the pathogenic role of IL-17 axis in primary Sjögren's syndrome: A new era for therapeutic targeting?. <i>Autoimmunity Reviews</i> , 2014, 13, 1167-1173.	2.5	36
114	Methotrexate: an old new drug in autoimmune disease. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1519-1530.	1.3	100
115	Is minor salivary gland biopsy more than a diagnostic tool in primary Sjögren's syndrome? Association between clinical, histopathological, and molecular features: A retrospective study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 314-324.	1.6	61
116	Potential of stem cells in the treatment of rheumatic disease. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 183-195.	0.3	0
117	Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy. <i>Autoimmunity Reviews</i> , 2013, 12, 709-716.	2.5	51
118	Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI). <i>European Journal of Radiology</i> , 2013, 82, e268-e273.	1.2	66
119	Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine. <i>Angiogenesis</i> , 2013, 16, 595-607.	3.7	61
120	Immunomodulation in psoriatic arthritis: Focus on cellular and molecular pathways. <i>Autoimmunity Reviews</i> , 2013, 12, 599-606.	2.5	83
121	Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. <i>Clinical and Experimental Immunology</i> , 2013, 173, 195-206.	1.1	59
122	Jejunioileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 441-452.	1.3	18
123	Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. <i>Arthritis Research and Therapy</i> , 2013, 15, R172.	1.6	143
124	Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 782-783.	0.5	29
125	Longterm Retention of Tumor Necrosis Factor- $\alpha$ Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors. <i>Journal of Rheumatology</i> , 2012, 39, 1179-1184.	1.0	87
126	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry. <i>Autoimmunity Reviews</i> , 2012, 12, 225-229.	2.5	146



#	ARTICLE	IF	CITATIONS
127	Cellular players in angiogenesis during the course of systemic sclerosis. <i>Autoimmunity Reviews</i> , 2011, 10, 641-646.	2.5	52
128	Angiogenic cytokines and growth factors in systemic sclerosis. <i>Autoimmunity Reviews</i> , 2011, 10, 590-594.	2.5	88
129	Angiogenesis in rheumatoid arthritis: A disease specific process or a common response to chronic inflammation?. <i>Autoimmunity Reviews</i> , 2011, 10, 595-598.	2.5	168
130	A genetic variation located in the promoter region of the <i>UPAR</i> ( <i>CD87</i> ) gene is associated with the vascular complications of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2011, 63, 247-256.	6.7	41
131	The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 598-605.	0.5	97
132	Association between a stromal cell-derived factor 1 ( <i>SDF-1/CXCL12</i> ) gene polymorphism and microvascular disease in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 408-411.	0.5	29
133	The $\gamma$ 670G>A polymorphism in the <i>FAS</i> gene promoter region influences the susceptibility to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 584-590.	0.5	34
134	Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: New insight into the pathogenesis of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2007, 56, 1994-2004.	6.7	138
135	Surface Expression of Fractalkine Receptor (CX3CR1) on CD4+/CD28 T Cells in RA Patients and Correlation with Atherosclerotic Damage. <i>Annals of the New York Academy of Sciences</i> , 2007, 1107, 32-41.	1.8	43
136	Variations of neuronal nitric oxide synthase in systemic sclerosis skin. <i>Arthritis and Rheumatism</i> , 2006, 54, 202-213.	6.7	18
137	Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications. <i>Arthritis and Rheumatism</i> , 2006, 54, 3022-3033.	6.7	64
138	Resistance to apoptosis in circulating alpha/beta and gamma/delta T lymphocytes from patients with systemic sclerosis. <i>Journal of Rheumatology</i> , 2006, 33, 2003-14.	1.0	15
139	Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. <i>Arthritis Research</i> , 2002, 4, R11.	2.0	230
140	Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. <i>Journal of Rheumatology</i> , 2002, 29, 731-6.	1.0	93
141	Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma). <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 487-494.	0.5	35
142	Serum levels of soluble CD30 are increased in ulcerative colitis (UC) but not in Crohn's disease (CD). <i>Clinical and Experimental Immunology</i> , 1998, 111, 532-535.	1.1	35